While several members expressed concerns about the data supporting the safety and efficacy of Indivior PLC's once-monthly injectable buprenorphine, a US FDA advisory panel voted 18 to 1 in favor of its approval with a Risk Evaluation and Mitigation Strategy (REMS) restricting distribution to certain healthcare settings.
Panelists agreed that the product, RBP-6000, provides an effective new treatment for opioid abuse disorder. Several felt the approval should...





